Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/695748
Genetic Engineering & Biotechnology News | GENengnews.com | JULY 2016 | 37 SONNTEK,INC. Classifed The International Biomedical Re- search Alliance named Harold Varmus, M.D., to its board of directors...Wilex appointed Andreas Pahl to its execu- tive management board...Illumina wel- comed Paula Dowdy as svp and GM of commercial operations for Europe, the Middle East and Africa...Five Prime Therapeutics hired Robert Sikorski, M.D., Ph.D., as CMO...Cleave Biosci- ences added Tim Smith as CBO..Bruce Stouffer is the new executive director of immunochemistry at Pharmaceutical Product Development...Agendia hired Gabriel Hortobagyi, M.D., as chairman to its medical advisory board. Eric Rhodes is now CEO of ERS Ge- nomics...Sunesis Pharmaceuticals added Linda Neuman, M.D., as vp of clini- cal development...ProNAi Therapeutics named Christian Hassig, Ph.D., as svp of research...nLife Therapeutics appointed Errol B. De Souza, Ph.D., as executive chairman...Eyevensys elected Patricia Zilliox, M.D., to its board of directors... Lakewood-Amedex welcomed Steve Mi- ley, M.D., as CMO and Steven A. Kates, Ph.D., as CSO and vp of regulatory af- fairs...Alkermes named Nancy Snyder- man, M.D., to its board of directors. Eric Scharf joined antibodies-online as vp, global brand development...Iqbal Husain, Ph.D., is now vp of program and portfolio management, Dauphine S. Bar- one is vp of manufacturing logistics, and Barbara A. Schaeffer is vp of clinical op- erations for Alder BioPharmaceuticals... Jeremy Haigh joined Proteome Sciences as CEO...Gilead Sciences added Kevin Young as COO and Martin Silverstein, M.D., as evo of strategy...Amplyx Pharmace named Paul C. Grint, M.D., to its board of direc- tors...Jennifer L. Herron is now evp and CCO of Ariad Pharmaceuticals. Silence Therapeutics welcomed Da- vid Ellam as CFO and director and Jörg Vollmer, Ph.D., and Kevin Mor- ris, Ph.D., to its technology advisory board...Sophia Genetics elected Alek- sandra Filipovic and Peter Wild to its scientific board...Genocea Biosciences hired John E. Bishop, Ph.D., as svp of pharmaceutical science....Cytokinetics named Edward M. Kaye, M.D., to its board of directors...Univac added Ste- fano Malvolti as CEO and Tyler Martin, M.D., as independent director and chair- man of its board of directors. Jarl Ulf Jungnelius, M.D., Ph.D., joined VAXIMM as CMO...Paul Hud- son is now CEO of Novartis Pharmaceu- ticals and Bruno Strigini CEO of Novar- tis Oncology...Wolfe Laboratories hired Paul Oakley as svp and general coun- sel...Fate Therapeutics added Chris M. Storgard, M.D., as CMO...Caldan Ther- apeutics welcomed Frank M Armstrong, M.D., as nonexecutive chairman, Philip Boyd, Ph.D., as CFO, Gerry Thomas, Ph.D., as COO, and Stephen Connolly, Ph.D., as vp of drug discovery. Jan Lötvall, M.D., Ph.D., joined Co- diak BioSciences as chief scientist... Coherus BioSciences welcomed Patrick O'Brien as svp, investor relations... Repros Therapeutics appointed Patrick Fourteau as chairman of its board...XBio- tech hired Dawn McCollough as vp of of clinical operations...Aeglea BioTherapeu- tics added Sandra Rojas-Caro, M.D., as CMO...Illumina appointed Jay Flatley as executive chairman of its board. PEOPLE Reprints 914-740-2194 reprints@GENengnews.com GEN offers reprints of individual articles — in print or electronic form Subscribe Clinical OMICs extends GEN's comprehensive coverage to the clinic by focusing on the application of revolutionary molecular technolo - gies in medical practice. To p i c s c ove re d i n c l u d e p e r s o n a l i z e d and precision medicine, next-gen sequencing, bioinformatics, reim - b u r s e m e n t , a n d b i o e t h i c s . To see past issues, recent news, and sub - scribe, go to: clinicalomics.com GEN'S NEW ePUB Molecular Diagnostics in Personalized Medicine Advanced Analytical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Advanced Cell Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Afymetrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Bachem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 BD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 BD Advanced Bioprocess . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 BioTek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Clinical OMICs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 GE Life Sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 GEN/Pall Life Sciences webinar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Integra Biosciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Lonza . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Molecular Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Organovo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 OriGene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Pall Life Sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 PerkinElmer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 PolyPeptide Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Roche Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Sonntek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 TriLink BioTechnologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Waters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Zymo Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Cover Tip A D V E R T I S E R I N D E X P R O F I L E Roger Morgan, M.D., is the new vp of medical afairs at MedSurgPI. In the past, Dr. Morgan was evp global medical afairs at Clinipace World- wide, CMO of Kowa Research Insti- tute, director of medical afairs/assis- tant research professor department of surgery at Duke University, and as senior direc- tor of medical/ scientifc services internal medi- cine therapeutics division at Quintiles. P R O F I L E Celmatix welcomed Erin Foran Wolf, M.D., as CMO. Before that, Dr. Wolf was an assistant clinical investigator at the NIH. In the past, she was an assistant profes- sor at the Uni- formed Services University of the Health Sciences School of Medicine, reproductive en- docrinology and infertility specialist at Shady Grove Fertility Center, repro- ductive endocrinology and infertil- ity fellow at the NIH, and associate research scientist at Yale University School of Medicine. Scott Schulz is the new director of North American operations at Envigo. Most recently, he was vp of opera- tions at Taconic Biosciences. In the past, Mr. Schulze was director of op- erations at Baxter Health and se- nior director of manufacturing operations at Cardinal Health. P R O F I L E Francis deSouza, is now presi- dent and CEO of Illumina. Before that, he was president of Illumina, president of products and services at Symantec, co-founder and CEO of IMlogi, and co-founder and CEO of Flash Communica- tions. Currently, Mr. deSouza is a board member at Illumina, and Citrix. P R O F I L E CORRECTIONS In the June 1 issue of GEN please note the following corrections. On p. 17 Lonza's Dr. Gregory Alberts was quoted as saying "We are in the process of beta testing a new large transfection device that will be able to transfect a billion to 20 billion cells in a format ranging from 1 to 20 mL." The frst part of the sentence should have read "… device that will be able to transfect 200 million to 1 billion cells." On p. 22 the correct title for Hans Johansson at Purolite is application manager.